Head and neck - oncology - SA Health Approved Cancer Chemotherapy Protocol Register
Definitive chemoradiation
Protocol | Administration at chemotherapy unit level | Review Date |
---|---|---|
Head and neck squamous cell carcinoma locally advanced cARBOplatin (weekly) chemoradiation (Part 2 of TPF) | Medium | August 2024 |
Head and neck squamous cell carcinoma locally advanced definitive cARBOplatin and fluorouracil chemoradiation | Medium | August 2024 |
Head and neck squamous cell carcinoma locally advanced definitive cetuximab chemoradiation | Medium | August 2024 |
Head and neck squamous cell carcinoma locally advanced definitive cISplatin (three weekly) chemoradiation | Medium | August 2023 |
Head and neck squamous cell carcinoma locally advanced definitive cISplatin (weekly) chemoradiation | Medium | August 2023 |
Induction chemotherapy
Protocol | Administration at chemotherapy unit level | Review Date |
---|---|---|
Head and neck squamous cell carcinoma locally advanced induction TPF (DOCEtaxel cISplatin fluorouracil) (part 1) | Medium | August 2024 |
Nasopharyngeal
Protocol | Administration at chemotherapy unit level | Review Date |
---|---|---|
Nasopharyngeal locally advanced adjuvant cARBOplatin and fluorouracil (following chemoradiation) | Medium | August 2024 |
Nasopharyngeal locally advanced adjuvant cISplatin and fluorouracil (following chemoradiation) | Medium | August 2024 |
Nasopharyngeal locally advanced cARBOplatin (weekly) chemoradiation | Medium | August 2024 |
Nasopharyngeal locally advanced ciSplatin and capecitabine (induction) | Medium | August 2024 |
Nasopharyngeal locally advanced ciSplatin and gemcitabine (induction) | Medium | August 2024 |
Nasopharyngeal locally advanced cISplatin (three weekly) chemoradiation | Medium | August 2024 |
Nasopharyngeal locally advanced cISplatin (weekly) chemoradiation | Medium | August 2024 |
Nasopharyngeal recurrent or metastatic cISplatin and gemcitabine | Medium Day 1 Low day 8 |
August 2024 |
Nasopharyngeal recurrent or metastatic gemcitabine | Low | August 2024 |
Post operative chemoradiation
Protocol | Administration at chemotherapy unit level | Review Date |
---|---|---|
Head and neck squamous cell carcinoma locally advanced post operative cISplatin (three weekly) chemoradiation | Medium | August 2024 |
Head and neck squamous cell carcinoma locally advanced post operative cISplatin (weekly) chemoradiation | Medium | August 2023 |
Recurrent or metastatic
Salivary gland
Protocol | Administration at chemotherapy unit level | Review Date |
---|---|---|
Head and neck salivary gland advanced CAP (CYCLOPHOSPHamide DOXOrubicin cISplatin) | Medium | February 2024 |
Head and neck salivary gland advanced or metastatic ciSplatin and vinORELBine | Medium | August 2026 |
Thyroid
Protocol | Administration at chemotherapy unit level | Review Date |
---|---|---|
Thyroid locally advanced or metastatic lenvatinib | Low | August 2023 |
Notes
- Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
- Fluorouracil pumps may be connected/disconnected at low-risk units
- Non-formulary drug included in the protocol
- Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.